文献速递冠心病

糖化血红蛋白与载脂蛋白A-1比值对急性冠脉综合征患者预后的预测价值

[Value of glycosylated hemoglobin A1c and apolipoprotein A-1 ratio on predicting outcome of patients with acute coronary syndrome].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2023-01-01

本研究为回顾性队列研究,纳入366例接受冠脉造影的ACS患者,随访(22.3±4.4)个月。校正年龄、收缩压、糖尿病病史及Gensini评分后,高HbA1c/ApoA-1组MACEs发生率是低组的2.45倍(95%CI 1.16-5.18,P=0.019),全因死亡率无显著差异。HbA1c/ApoA-1比值与Gensini评分呈正相关(r=0.274,P<0.01),提示其可作为ACS风险分层潜在生物标志物。

要点

  • 高HbA1c/ApoA-1比值是ACS患者MACEs的独立危险因素(校正后HR 2.45,95%CI 1.16-5.18,P=0.019)。
  • 高HbA1c/ApoA-1组患者冠脉病变程度更重,比值与Gensini评分正相关(r=0.274,P<0.01)。
  • HbA1c/ApoA-1可能用于ACS早期高危识别和MACEs预测,但全因死亡率组间无差异(P=1.000)。

核心结论

  • 高HbA1c/ApoA-1比值是ACS患者MACEs的独立危险因素,且与更重的冠状动脉病变程度相关。
  • HbA1c/ApoA-1比值可能作为ACS患者心血管风险分层的潜在生物标志物。

研究设计与样本

  • 回顾性队列研究,连续入选2017年3月至2019年3月于北京医院住院并接受冠状动脉造影的ACS患者366例。
  • 按HbA1c/ApoA-1水平三分位数分为高(5.87-16.12)、中(4.50-5.83)、低(2.11-4.48)三组。
  • 采用Cox比例风险模型评估MACEs和全因死亡率差异,Kaplan-Meier生存分析比较无MACEs生存率,Spearman秩相关分析评价HbA1c/ApoA-1与Gensini评分的相关性。

主要发现

  • 平均年龄(65.9±10.3)岁,随访(22.3±4.4)个月期间共发生59例MACEs和10例全因死亡。
  • 校正年龄、收缩压、糖尿病病史及Gensini评分后,高HbA1c/ApoA-1组MACEs发生率是低组的2.45倍(95%CI 1.16-5.18,P=0.019)。
  • 高HbA1c/ApoA-1组与低组全因死亡率差异无统计学意义(P=1.000)。
  • Kaplan-Meier生存分析显示高HbA1c/ApoA-1组MACEs风险最高、低组最低(P<0.01)。
  • Spearman秩相关分析显示HbA1c/ApoA-1比值与Gensini评分呈正相关(r=0.274,P<0.01)。

临床怎么用

  • 对ACS患者可检测HbA1c与ApoA-1并计算比值,辅助识别MACEs高危人群。
  • 高HbA1c/ApoA-1比值提示冠脉病变程度可能更重,需加强风险评估与随访管理。

局限性

  • 本研究为单中心回顾性队列研究,样本量366例,结论需更大规模前瞻性研究验证。
  • 全因死亡事件仅10例,死亡率分析效能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the predictive value of glycosylated hemoglobin A1c/apolipoprotein A-1 (HbA1c/ApoA-1) ratio for major adverse cardiovascular events (MACEs) in patients with acute coronary syndrome (ACS). Methods: The present study is a retrospective cohort study. ACS patients who were hospitalized and underwent coronary angiography at Beijing Hospital from March 2017 to March 2019 were enrolled. Baseline information such as sex, age, previous history, Gensini score, HbA1c and ApoA-1 were analyzed. Patients were divided into two groups according to presence or absence of MACEs and the difference on HbA1c/ApoA-1 ratio was compared between the two groups. According to the tertiles of HbA1c/ApoA-1 levels, patients were divided into high (5.87-16.12), medium (4.50-5.83) and low (2.11-4.48) HbA1c/ApoA-1 groups. Cox proportional risk model was used to evaluate the differences in MACEs and all-cause mortality among the three groups. Kaplan-Meier survival analysis was used to compare the differences of MACEs between the various HbA1c/ApoA-1 groups. Results: A total of 366 ACS patients were included in this study. The mean age of the patients was (65.9±10.3) years. There were 59 MACEs and 10 all-cause deaths during the mean of (22.3±4.4) months follow-up. After adjusting for age, systolic blood pressure, history of diabetes and Gensini score, the incidence of MACEs was 2.45 times higher in the high HbA1c/ApoA-1 group than in the low HbA1c/ApoA-1 group (95%CI 1.16-5.18, P=0.019). There was no significant difference in all-cause mortality between the high and low HbA1c/ApoA-1 groups (P=1.000). Kaplan-Meier survival analysis showed that patients in the high HbA1c/ApoA-1 group had the highest risk of MACEs, while patients in the low HbA1c/ApoA-1 group had the lowest risk of MACEs (P<0.01). Spearman rank correlation analysis showed that HbA1/ApoA-1 ratio was positively correlated with Gensini score in ACS patients (r=0.274, P<0.01). Conclusion: High HbA1c/ApoA-1 ratio was an independent risk factor for MACEs in ACS patients. Patients with high HbA1c/ApoA-1 ratio had more severe coronary artery disease lesions. HbA1c/ApoA-1 ratio may be used as a potential risk stratification biomarker for ACS patients, it might be useful for the early identification of high-risk population and for predicting the incidence of MACEs among ACS patients. 目的: 探讨糖化血红蛋白A1c(HbA1c)与载脂蛋白A-1(ApoA-1)比值(HbA1c/ApoA-1)对急性冠状动脉综合征(ACS)患者随访期间主要不良心血管事件(MACEs)的预测价值。 方法: 本研究为回顾性队列研究,连续入选2017年3月至2019年3月于北京医院住院并接受冠状动脉造影的ACS患者,收集性别、年龄、既往史、Gensini评分、HbA1c和ApoA-1等基线资料。依据随访期间有无MACEs发生分为MACEs组和无MACEs组,分析2组间HbA1c/ApoA-1的差异。按HbA1c/ApoA-1水平的三分位数将患者分为高、中、低HbA1c/ApoA-1组,使用Cox比例风险模型评估3组间MACEs、全因死亡率等终点事件的差异。使用Kaplan-Meier生存分析比较各HbA1c/ApoA-l组间无MACEs生存率差异。使用Spearman秩相关分析评价HbA1c/ApoA-1与Gensini评分的相关性。 结果: 共纳入ACS患者366例,59例发生MACEs,10例发生全因死亡。所有患者平均年龄为(65.9±10.3)岁,随访(22.3±4.4)个月,校正年龄、收缩压、糖尿病病史、冠状动脉病变严重程度后,高HbA1c/ApoA-1组患者MACEs发生率是低HbA1c/ApoA-1组患者的2.45倍(95%CI:1.16~5.18,P=0.019),但2组全因死亡率差异无统计学意义(P=1.000)。Kaplan-Meier生存分析显示高HbA1c/ApoA-l组MACEs风险最高,低HbA1c/ApoA-l组风险最低,差异有统计学意义(P<0.01)。Spearman秩相关分析结果显示,HbA1c/ApoA-1比值高低与ACS患者Gensini评分呈正相关(r=0.274,P<0.01)。 结论: HbA1c/ApoA-1是ACS患者MACEs的独立危险因素。高HbA1c/ApoA-1患者冠状动脉病变程度更重。HbA1c/ApoA-1水平可能作为评估ACS患者心血管风险的潜在指标,用于早期识别高危人群,预测MACEs的发生。.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wang, Mu, Yang, et al. [Value of glycosylated hemoglobin A1c and apolipoprotein A-1 ratio on predicting outcome of patients with acute coronary syndrome]. Zhonghua Xin Xue Guan Bing Za Zhi. 2023. PMID: 36655240. doi:10.3760/cma.j.cn112148-20221011-00791

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。